Department of Community Healthcare and Geriatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan.
Hypertension. 2014 Mar;63(3):607-15. doi: 10.1161/HYPERTENSIONAHA.113.02141. Epub 2013 Dec 16.
Cathepsin K (CatK) is one of the most potent mammalian collagenases. We showed previously the increased expression of CatK in human and animal atherosclerotic lesions. Here, we hypothesized that ablation of CatK mitigates injury-induced neointimal hyperplasia. Male wild-type (CatK(+/+)) and CatK-deficient (CatK(-/-)) mice underwent ligation or a combination of ligation and polyethylene cuff-replacement injuries to the right common carotid artery just proximal to its bifurcation, and they were then processed for morphological and biochemical studies at specific time points. On operative day 28, CatK(-/-) significantly reduced neointimal formation and neovessel formation in both single- and combination-injured arteries compared with the Cat K(+/+) mice. At early time points, CatK(-/-) reduced the lesion macrophage contents and medial smooth muscle cell proliferation, the mRNA levels of monocyte chemoattractant protein-1, toll-like receptor-2, toll-like receptor-4, chemokine ligand-12, and the gelatinolytic activity related to matrix metalloproteinase-2/-9. An aorta-explant assay revealed that smooth muscle cell movement was impaired in the CatK(-/-) mice compared with the CatK(+/+) mice. In addition, the smooth muscle cells and macrophages from CatK(-/-) mice had less invasive ability through a reconstituted basement membrane barrier. This vasculoprotective effect was mimicked by Cat inhibition with trans-epoxysuccinyl-L-leucylamido-{4-guanidino} butane (E64d). These results demonstrate an essential role of CatK in neointimal lesion formation in response to injury, possibly via the reduction of toll-like receptor-2/-4-mediated inflammation and smooth muscle cell proliferation, suggesting a novel therapeutic strategy for the control of endovascular treatment-related restenosis by regulating CatK activity.
组织蛋白酶 K(CatK)是最有效的哺乳动物胶原酶之一。我们之前曾表明,CatK 在人类和动物动脉粥样硬化病变中的表达增加。在这里,我们假设 CatK 的消融可减轻损伤诱导的新生内膜增生。雄性野生型(CatK(+/+))和 CatK 缺失型(CatK(-/-))小鼠在其分叉前的右侧颈总动脉进行结扎或结扎加聚乙烯袖套更换损伤,然后在特定时间点进行形态学和生化研究。在手术第 28 天,与 Cat K(+/+)小鼠相比,CatK(-/-)小鼠在单一和联合损伤的动脉中明显减少了新生内膜形成和新血管形成。在早期时间点,CatK(-/-)减少了病变巨噬细胞含量和中膜平滑肌细胞增殖,单核细胞趋化蛋白-1、Toll 样受体-2、Toll 样受体-4、趋化因子配体-12 和与基质金属蛋白酶-2/-9 相关的明胶酶活性的 mRNA 水平。主动脉外植体测定显示,与 Cat K(+/+)小鼠相比,CatK(-/-)小鼠的平滑肌细胞运动受损。此外,CatK(-/-)小鼠的平滑肌细胞和巨噬细胞通过重建的基底膜屏障的侵袭能力降低。Cat 抑制剂反式-环氧琥珀酰-L-亮氨酰酰胺基-4-胍基丁烷(E64d)模拟了这种血管保护作用。这些结果表明 CatK 在损伤后新生内膜病变形成中起重要作用,可能通过减少 Toll 样受体-2/-4 介导的炎症和平滑肌细胞增殖来实现,这提示通过调节 CatK 活性来控制血管内治疗相关再狭窄的新治疗策略。